Glutamine Antagonist DRP-104 in Combination with Durvalumab in Patients with Advanced Fibrolamellar Carcinoma (FLC) Following Progression on Prior Anti-Pd(l)1 Therapy.
Journal of Clinical Oncology（2024）
Key words
298-145-222-184-4809-5347,261-492-3532-2370-7650-2700,261-566-9718-9794,2002,2002,2018,2018,38092-30118,38092-21813,38092-27449
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined